|
Rolf Soiron (1945) Holds a PhD in philosophy from the University of Basel and a Post Master degree from the Harvard Business School
- Chairman of the Board of Directors of Lonza Group Ltd (since April 2005)
- Chairman of the Board of Directors of Nobel Biocare Holding Ltd, Zürich (since 2003)
- Chairman of the Board of Directors of Holcim Ltd, Jona (since 2003) and member of the Board (since 1994)
- Member of the Board of Directors of Jungbunzlauer Group, Basel (since 1993)
- Managing Director of Jungbunzlauer Group, Basel (2001 - 2003)
- CEO of Jungbunzlauer Group, Basel (1993 - 2001)
- Sandoz Group - COO and Head of Pharma in Basel (1992 - 1993), Group Vice-President Agribusiness USA in New York (1988 - 1992)
- Protek Group (orthopedic implants) President and CEO in Berne (1983 - 1987)
- Sandoz Group - various functions in Human Resources, Finance and Corporate in Basel (1972 - 1983)
- Chairman of the Basel University Council (1995 - 2005)
|
|
Sir Richard Sykes (1942) PhD in microbial biochemistry from Bristol University and DSc from the University of London. Fellow of The Royal Society. Member of a number of government and scientific committees.
Holds a number of honorary degrees and awards from institutions both in the UK and overseas. Received his knighthood in the New Year Honours List for services to the pharmaceutical industry (1994).
- Vice Chairman of the Board of Directors of Lonza Group Ltd, Basel (since April 2005)
- Member of the Board of Directors of Lonza Group Ltd, Basel (since March 2003)
- Chairman of NHS London (since December 2008)
- Member of the Board of Directors of ENRC plc, London (since 2007)
- Rector of Imperial College, London (2001 - 2008)
- Member of the Board of Directors of Rio Tinto plc (1997 - 2008)
- Chairman and Chief Executive of Glaxo Wellcome plc, London (1997-2002)
- Served as President of the British Association for the Advancement of Science (1998-1999)
- Deputy Chairman and Chief Executive of Glaxo plc (1993-1997)
- Deputy Chief Executive of Glaxo Group Research Ltd, London, and Group Research and Development Director of Glaxo plc, London, and Chairman and Chief Executive of Glaxo Group Research Ltd (1987-1993)
- Vice-President, Infectious and Metabolic Diseases, Squibb Institute for Medical Research, Princeton, New Jersey (1983-1986)
- Director of Microbiology and Associate Director, Squibb Institute for Medical Research, Princeton, New Jersey (1979-1982)
- Head of the Antibiotic Research Unit of Glaxo Research Ltd, London (1972-1978)
|
|
Patrick Aebischer (1954) – MD and Dr in medicine from the University of Geneva. Has received numerous honours, including the Robert Bing Prize of the Swiss Academy of Medical Sciences and the Pfizer Foundation Prize for Clinical Neurosciences.
- Member of the Board of Directors of Lonza Group Ltd, Basel (since March 2008)
- President of the Swiss Federal Institute of Technology (EPFL), Lausanne (since 2000)
- Professor of Neurosciences, Swiss Federal Institute of Technology (EPFL), Lausanne (since 2000)
- Fellow of the American Institute for Medical and Biological Engineering (since 2000)
- Fellow of the Swiss Academy of Medical Sciences (since 1998)
- Founder of three biotechnology companies
|
|
Dame Julia Higgins (1942) Holds a B.A. Honours in Physics and a D.Phil. from the Department of Physical Chemistry at the University of Oxford. Fellow and member of a number of scientific institutions in the UK and overseas, e.g. Royal Society, Royal Academy of Engineering, Royal Society of Chemistry and the American Chemical Society. Honored with the DBE (Dame Commander of the Order of the British Empire).
- Member of the Board of Directors of Lonza Group Ltd, Basel (since March 2006)
- President of the Association for Science Education (2007 - 2008)
- Principal of the Faculty of Engineering, Imperial College London (2006 - 2007)
- Chairman of the Engineering and Physical Sciences Research Council (2003 - 2007)
- Foreign Secretary and Vice President of The Royal Society (2001 - 2006)
- Trustee of The National Gallery (since 2001)
- Daphne Jackson Memorial Fellowships, Trustee (since 1994)
- Professor of Polymer Science, Imperial College London, Department of Chemical Engineering and Chemical Technology (since 1989); Emeritus and Senior Research Investigator (from 2007)
|
|
Frits van Dijk (1947) studied Economics in Rotterdam, The Netherlands
- Member of the Board of Directors of Lonza Group Ltd, Basel (since April 2009)
- Spent his entire carreer with Nestlé (since 1970) of which 28 years in Asia (1972 – 2000: India, Philippines, Sri Lanka, Malaysia, China, Japan). Was Chairman & CEO of Nestlé Waters Worldwide (2000 – 2005 ), after which he took on his current responsibility as Head for the Nestlé operations in Asia, Oceania, Africa and the Middle East, based at the Nestlé Headquarters in Vevey, Switzerland
- Member of the Nestlé Executive Board (since 2001)
- Member of the Board of several Nestlé operations / Joint Ventures
- Chair of the Consumer Industry Steering Board at the WEF
|
|
Gerhard Mayr (1946) Holds a Masters Degree in Chemical Engineering from the Swiss Federal Institute of Technology (ETH), Zurich, and a Master of Business Administration from Stanford University.
- Member of the Board of Directors of Lonza Group Ltd, Basel (since March 2006)
- Member of the Board of UCB SA, Brussels (since 2005)
- Member of the Board of Directors of OMV AG, Vienna (since 2002)
- Member of the Board of Bank Austria AG, Vienna (1998 - 2004)
- Executive Vice President of Eli Lilly & Company with responsibility for global pharmaceutical operations (1999-2004)
- President of Ely Lilly Intercontinental (1997 - 1999)
- President of Ely Lilly International (1993 - 1997)
- Joined Ely Lilly in 1972 as Sales Representative
- Member of the Board of Project Hope, USA (since 2002)
- Member of the Board of the Vienna Science, Research and Technology Foundation (since 2002)
- Member of the circle of patrons of INSEAD Business School (since 2000)
- Member of the US-Egypt President’s Council (1999-2004)
- Member of the Board of the European Federation of the Pharmaceutical Industry (1995-1997 and 2000-2002)
|
|
Peter Wilden (1957) Holds a degree in business administration and information technology, as well as a PhD in business administration from the University of Kiel.
- Member of the Board of Directors of Lonza Group Ltd, Basel (since March 2004)
- Executive Vice-President Finance and Chief Financial Officer of Ferring Pharmaceuticals in Lausanne (since 2000)
- Member of the Board of Trace Biotech AG, Braunschweig (1999-2002)
- Held various managerial positions in the Ferring Group (1991 - 2000)
- Consultant on a number of IT and related projects at Mak Data System, Kiel, and within the Krupp network (1988-1991)
- Management Assistant with Krupp MaK Maschinenbau GmbH, Kiel (1986-1988)
- Scientific Assistant in the IT-Group of the Kiel Institute of World Economics (1983-1986)
- Member of various scientific research organizations in Germany, the United States and in the Netherlands
|
|
|
